Cargando…
Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
INTRODUCTION: Alterations in the MET gene, including amplifications and exon 14 skipping mutations, have been identified as actionable oncogenic alterations. However, MET fusions are rarely detected in lung cancer, and their sensitivity to therapeutics has not been systematically analyzed. METHODS:...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960416/ https://www.ncbi.nlm.nih.gov/pubmed/36829199 http://dx.doi.org/10.1186/s12967-023-03999-7 |